Eisai resubmits Perampanel NDA to FDA

Tuesday, December 27, 2011 01:28 PM

Eisai has resubmitted the New Drug Application (NDA) for the investigational AMPA-type glutamate receptor antagonist perampanel for partial-onset seizures associated with epilepsy to the FDA. This resubmission comes after the FDA issued a Refusal to File letter in July 2011 in which FDA requested reformatting and reanalyses of some datasets in the dossier. The application was originally submitted in May 2011.

The FDA will determine acceptance of filing within 60 days of submission.

Featured Jobs

About CenterWatch News Online: Developed by CenterWatch, the trusted experts and recognized leaders in clinical research news and analysis, CenterWatch News Online (formerly Clinical Trials Today) is a one-stop, comprehensive resource for clinical research professionals spanning all sectors of the clinical trials industry.

Order Custom PDF Reprints: CenterWatch offers custom PDF reprints of any new or archived article appearing on CenterWatch News Online. This document can be posted on your company's Intranet or web site or used in corporate marketing promotions.To purchase a custom PDF reprint, contact Sales at sales@centerwatch.com or (617) 948-5100.